Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

469
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
469
Pleiotropy01:33

Pleiotropy

41.8K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
41.8K
Tumor Progression02:07

Tumor Progression

6.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.7K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

358
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
358
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

3.3K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.3K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.5K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026
Same author

Performance of Age-Adjusted Whole Genome Sequencing Telomere Length in Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026
Same author

Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

The New England journal of medicine·2026
Same author

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

The New England journal of medicine·2026
Same author

Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.

BMJ open respiratory research·2026
Same author

A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2025

Related Experiment Video

Updated: Oct 29, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.3K

The justification for the progressive fibrotic phenotype.

Martin Rj Kolb1, Kevin R Flaherty2

  • 1McMaster University, Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ontario, Canada.

Current Opinion in Pulmonary Medicine
|July 7, 2021
PubMed
Summary

Progressive fibrotic interstitial lung disease (ILD) requires accurate diagnosis for tailored therapy. Antifibrotic therapy may benefit various ILDs once fibrosis progresses, regardless of the initial cause.

More Related Videos

Identification, Isolation, and Characterization of Fibro-Adipogenic Progenitors FAPs and Myogenic Progenitors MPs in Skeletal Muscle in the Rat
09:49

Identification, Isolation, and Characterization of Fibro-Adipogenic Progenitors FAPs and Myogenic Progenitors MPs in Skeletal Muscle in the Rat

Published on: June 9, 2021

6.4K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

474

Related Experiment Videos

Last Updated: Oct 29, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.3K
Identification, Isolation, and Characterization of Fibro-Adipogenic Progenitors FAPs and Myogenic Progenitors MPs in Skeletal Muscle in the Rat
09:49

Identification, Isolation, and Characterization of Fibro-Adipogenic Progenitors FAPs and Myogenic Progenitors MPs in Skeletal Muscle in the Rat

Published on: June 9, 2021

6.4K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

474

Area of Science:

  • Pulmonology
  • Fibrotic Interstitial Lung Disease

Background:

  • Accurate diagnosis of interstitial lung disease (ILD) is crucial for guiding therapy and prognosis.
  • Idiopathic pulmonary fibrosis (IPF) diagnosis prompts antifibrotic therapy and avoidance of immunosuppression due to high progression risk.
  • Some non-IPF ILDs can progress to significant fibrosis, impacting quality of life and survival, necessitating targeted treatment.

Purpose of the Study:

  • To describe the concept of progressive fibrotic interstitial lung disease (ILD).
  • To review recent data and clinical rationale for identifying a progressive fibrotic phenotype in ILD.
  • To highlight the role of antifibrotic therapy in managing progressive fibrosis across different ILD types.

Main Methods:

  • Review of current clinical data and therapeutic strategies for ILD.
  • Analysis of diagnostic criteria and prognostic indicators for fibrotic ILDs.
  • Evaluation of the biological pathways involved in ILD progression.

Main Results:

  • A progressive fibrotic phenotype can occur in various ILDs, irrespective of the initial diagnosis.
  • Antifibrotic therapy shows potential efficacy in managing established fibrosis due to common underlying pathways.
  • Distinguishing IPF from other ILDs is critical for initial treatment, but progressive fibrosis may necessitate similar therapeutic approaches.

Conclusions:

  • Recognizing a progressive fibrotic phenotype in ILD is clinically relevant for treatment decisions.
  • Antifibrotic agents may offer a common therapeutic strategy for progressive fibrosis in diverse ILDs.
  • Understanding the fibrotic phenotype complements initial diagnosis for improved patient outcomes in ILD.